APLM vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
APLM's Piotroski F-Score of 3/9 indicates weak financial health, with significant red flags in profitability, cash flow, and leverage. The company exhibits extreme negative profitability metrics, including a -124.8% operating margin and -380.13% ROE, despite a 380.8% YoY revenue growth. With no Altman Z-Score available and a current ratio of 0.97, liquidity concerns persist. The stock trades at a high Price/Sales of 6.15 and a negative forward P/E of -30.62, suggesting valuation is driven by speculative growth expectations rather than fundamentals. The 52-week price range of $3.66 to $42.12 reflects extreme volatility, and the 5-year return of -98.0% underscores long-term underperformance.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
APLM vs JNJ: Head-to-Head Comparison
This page compares Apollomics, Inc. (APLM) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.